Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

TRIPLACE Registry: Conduction Disorders Following Transcatheter Tricuspid Valve Replacement

Tricuspid regurgitation (TR) has become increasingly common and has been associated to hospitalization for cardiac failure and increased mortality. 

The current guidelines continue to recommend surgical replacement, despite its 8 to 12% mortality, according to different series. 

Transcatheter tricuspid valve replacement (TTVR) is being looked at and different randomized trials have shown promising results. However, several questions remain unanswered, among them, post procedural conduction disorders. 

This analysis of the TRIPLACE registry (Global Multicenter Registry on Transcatheter Tricuspid Valve Replacement), included 185 inoperable severe TR patients with no prior definite pacemaker treated with TTVR.

The primary outcome was high grade atrioventricular (AV) block at 30 days. 

Mean patient age was 76, and they were mostly women. Mean TRISCORE was 14. Close to 90% were in functional class II-III, and over 40% had been hospitalized within12 months prior procedure. Also, 68% had hypertension, 27% diabetes, 49% kidney function deterioration, 14% COPD, 11% peripheral vascular disease, 77% peripheral edema, 24% ascites, 5% a history of TAVR, 5% CABG and 5% tricuspid surgery. 

Read also: Conduction Disorders in TAVR: Is Colchicine Useful?

The most frequent TR etiology was secondary (84%), followed by primary and in lower proportion mixed. Most predominant TR degree was torrential (44%), followed by severe (33%) and massive in the remaining cases.

At baseline EKG, 88% presented atrial fibrillation, 6% first degree AV block, 23% complete right bundle branch block (RBBB), 10% incomplete RBBB, 3% complete left BBB, 7% anterior or posterior fascicular block, and 2.7% bifascicular block.

As regards devices, the EVOQUE was used in 75 patients, the LUX PLUS in 53, CARDIOVALVE in 29 and others in 28.

Read also: Abbreviated Dual Antiplatelet Therapy with Prasugrel: 4D-ACS.

The primary outcome was seen in 13.5% (25 patients). Most high grade AV blocks were seen during the first week after procedure (88%). The need for pacemaker implantation was 11.9% (45% leadless, 27.3% coronary sinus leads, and the rest with other techniques. Malapposition was observed in 5 patients, and there was no embolization, migration or mortality. 

Complete or fascicular LBBB (anterior or posterior) at baseline was associated with higher risk of high grade AV block. 

Conclusion

High grade AV block was observed in 13.5% of patients undergoing transcatheter tricuspid valve replacement, mostly during the first week after procedure. The presence of complete / fascicular LBBB at baseline was significantly associated to high grade AV block after TTVR. 

Original Title: Incidence, Predictors, and Management of Conduction Disturbances After Transcatheter Tricuspid Valve Replacement. The TRIPLACE Registry.

Reference: Andrea Scotti,et al. JACC Cardiovasc Interv. 2025;18:1789–1799.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...